Inventor · disambiguated record
Joshua Hansen
Also filed as: HANSEN JOSHUA · HANSEN JOSHUA D
42 granted patents·20 pending applications·204 citations·filing 2009–2024
97Inventor score
Files withCELGENE CORP38SIGNAL PHARM LLC11TREELINE BIOSCIENCES INC6BRISTOL MYERS SQUIBB CO3AHRENDT KATERI A2
Top patents by PatentIndex Score
62 records- 0197US9512124B2Substituted aminopurine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2015·Granted Dec 6, 2016·32 cites·60 claims
- 0297US9499514B2Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2015·Granted Nov 22, 2016·28 cites·29 claims
- 0396US11634407B2Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2021·Granted Apr 25, 2023·5 cites·66 claims
- 0496US11185543B2Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2020·Granted Nov 30, 2021·5 cites·20 claims
- 0596US11149007B2Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2019·Granted Oct 19, 2021·14 cites·41 claims
- 0696US9737541B2Substituted aminopurine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2016·Granted Aug 22, 2017·12 cites·52 claims
- 0795US10357489B2Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2018·Granted Jul 23, 2019·20 cites·26 claims
- 0894US11325889B2Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2019·Granted May 10, 2022·11 cites·35 claims
- 0994US9808451B2Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2016·Granted Nov 7, 2017·12 cites·19 claims
- 1093US11873283B2Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2021·Granted Jan 16, 2024·2 cites·34 claims
- 1193US11739075B2Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2021·Granted Aug 29, 2023·3 cites·17 claims
- 1293US11560371B2Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2021·Granted Jan 24, 2023·3 cites·18 claims
- 1392US9968596B2Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2017·Granted May 15, 2018·8 cites·26 claims
- 1490US11241423B2Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2019·Granted Feb 8, 2022·2 cites·6 claims
- 1590US10227325B2Antiproliferative compounds, and their pharmaceutical compositions and usesCELGENE CORP·Filed 2018·Granted Mar 12, 2019·6 cites·18 claims
- 1689US9556126B2Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2014·Granted Jan 31, 2017·10 cites·32 claims
- 1788US10398700B2Substituted aminopurine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2018·Granted Sep 3, 2019·2 cites·11 claims
- 1888US9938254B2Antiproliferative compounds, and their pharmaceutical compositions and usesCELGENE CORP·Filed 2017·Granted Apr 10, 2018·5 cites·33 claims
- 1987US10149849B2Substituted aminopurine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2017·Granted Dec 11, 2018·2 cites·3 claims
- 2086US11726080B2Methods for treating multiple myeloma and the use of companion biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrileCELGENE CORP·Filed 2021·Granted Aug 15, 2023·1 cites·21 claims
- 2186US9156798B2Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2015·Granted Oct 13, 2015·5 cites·30 claims
- 2285US10940152B2Substituted aminopurine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2020·Granted Mar 9, 2021·1 cites·27 claims
- 2384US12510533B2Methods for treating multiple myeloma and the use of companion biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrileCELGENE CORP·Filed 2023·Granted Dec 30, 2025·0 cites·18 claims
- 2484US10646493B2Substituted aminopurine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2019·Granted May 12, 2020·1 cites·20 claims
- 2584US2023158035A1Substituted aminopurine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2023·Application pending·0 cites
- 2682US11358952B2Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2019·Granted Jun 14, 2022·1 cites·21 claims
- 2782US10969381B2Methods for treating multiple myeloma and the use of companion biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrileCELGENE CORP·Filed 2019·Granted Apr 6, 2021·1 cites·16 claims
- 2882US2024207255A1Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2024·Application pending·0 cites
- 2981US12404241B2Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2023·Granted Sep 2, 2025·0 cites·16 claims
- 3080US2024217955A1Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2024·Application pending·0 cites
- 3179US12187699B2GSPT1 compounds and methods of use of the novel compoundsBRISTOL MYERS SQUIBB CO·Filed 2023·Granted Jan 7, 2025·0 cites·2 claims
- 3279US9783505B2Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2016·Granted Oct 10, 2017·2 cites·29 claims
- 3379US2022387413A1Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2021·Application pending·0 cites
- 3478US10618883B2Antiproliferative compounds, and their pharmaceutical compositions and usesCELGENE CORP·Filed 2019·Granted Apr 14, 2020·1 cites·15 claims
- 3578US2025188056A1Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2024·Application pending·0 cites
- 3678US2025092012A1Gspt1 compounds and methods of use of the novel compoundsBRISTOL MYERS SQUIBB CO·Filed 2024·Application pending·0 cites
- 3777US12029738B2Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2021·Granted Jul 9, 2024·0 cites·23 claims
- 3877US11945804B2Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2022·Granted Apr 2, 2024·0 cites·23 claims
- 3977US8394795B2Pyrazole [3, 4-B] pyridine Raf inhibitorsAHRENDT KATERI A·Filed 2009·Granted Mar 12, 2013·5 cites·45 claims
- 4076US12103920B2Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2023·Granted Oct 1, 2024·0 cites·15 claims
- 4176US8338452B2Raf inhibitor compounds and methods of use thereofAHRENDT KATERI A·Filed 2009·Granted Dec 25, 2012·4 cites·49 claims
- 4275US11590139B2Substituted aminopurine compounds, compositions thereof, and methods of treatment therewithSIGNAL PHARM LLC·Filed 2021·Granted Feb 28, 2023·0 cites·52 claims
- 4373US2024208937A1Compounds and Their Use for Treatment of HemoglobinopathiesBRISTOL MYERS SQUIBB CO·Filed 2023·Application pending·0 cites
- 4472US12227490B2Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2023·Granted Feb 18, 2025·0 cites·18 claims
- 4569US11365184B2Antiproliferative compounds, and their pharmaceutical compositions and usesCELGENE CORP·Filed 2020·Granted Jun 21, 2022·0 cites·12 claims
- 4669US10675281B2Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2019·Granted Jun 9, 2020·0 cites·20 claims
- 4768US12486281B2Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2022·Granted Dec 2, 2025·0 cites·25 claims
- 4868US2024287091A1Tricyclic quinolone bcl6 bifunctional degradersTREELINE BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 4968US2025276981A1Tricyclic quinolone bcl6 bifunctional degradersTREELINE BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 5065US11312699B2Processes for preparing 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamideCELGENE CORP·Filed 2020·Granted Apr 26, 2022·0 cites·24 claims
Showing the top 50 of 62 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Joshua Hansen files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →